(6-bromo-pyrazolo[1,5-a]pyrimidin-2-yl)-(1-methyl-6-trifluoromethyl-3,4-dihydro-1H-cinnolin-2-yl)-methanone | 1174649-87-6

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯氮卓类
• 英文名称: (6-bromo-pyrazolo[1,5-a]pyrimidin-2-yl)-(1-methyl-6-trifluoromethyl-3,4-dihydro-1H-cinnolin-2-yl)-methanone
• 英文别名: (6-bromopyrazolo[1,5-a]pyrimidin-2-yl)-[1-methyl-6-(trifluoromethyl)-3,4-dihydrocinnolin-2-yl]methanone
• CAS: 1174649-87-6
• 化学式: C₁₇H₁₃BrF₃N₅O
• 分子量: 440.222
• InChiKey: XMGFZICKPPCUHH-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.7
• 重原子数：
  27
• 可旋转键数：
  1
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.24
• 拓扑面积：
  53.7
• 氢给体数：
  0
• 氢受体数：
  7

反应信息

• 作为产物：
  描述：

  6-溴吡唑并[1,5-A]嘧啶-2-羧酸 、 1-Methyl-6-trifluoromethyl-1,2,3,4-tetrahydro-cinnoline 生成 (6-bromo-pyrazolo[1,5-a]pyrimidin-2-yl)-(1-methyl-6-trifluoromethyl-3,4-dihydro-1H-cinnolin-2-yl)-methanone
  参考文献：
  名称：

  PYRAZOLOPYRIMIDINES, A PROCESS FOR THEIR PREPARATION AND THEIR USE AS MEDICINE

  摘要：

  本发明涉及吡唑并嘧啶衍生物及其药学上可接受的盐。本发明还涉及制备这些化合物的方法。本发明的化合物是mGluR5调节剂，因此对于控制和预防急性和/或慢性神经系统疾病有用。

  公开号：

  US20110003820A1

文献信息

• Pyrazolopyrimidines, a process for their preparation and their use as medicine
  申请人：Merz Pharma GmbH & Co. KGaA

  公开号：EP2085398A1

  公开（公告）日：2009-08-05

  The invention relates to pyrazolopyrimidine derivatives of Formula I wherein R1 represents chloro or bromo; A represents as well as their pharmaceutically acceptable salts. The invention further relates to a process for the preparation of such compounds. The compounds of the invention are mGluR5 modulators and are therefore useful for the control and prevention of acute and/or chronic neurological disorders.

  本发明涉及以下式子的吡唑嘧啶衍生物（I）： 其中R1代表氯或溴； A代表 以及其药学上可接受的盐。本发明还涉及制备这种化合物的方法。本发明的化合物是mGluR5调节剂，因此对于控制和预防急性和/或慢性神经系统疾病有用。
• [EN] PYRAZOLOPYRIMIDINES, A PROCESS FOR THEIR PREPARATION AND THEIR USE AS MEDICINE<br/>[FR] PYRAZOLOPYRIMIDINES, LEUR MÉTHODE DE PRÉPARATION ET LEUR UTILISATION COMME MÉDICAMENTS
  申请人：MERZ PHARMA GMBH & CO KGAA

  公开号：WO2009095254A1

  公开（公告）日：2009-08-06

  The invention relates to pyrazolopyrimidine derivatives of Formula (I) wherein R1 represents chloro or bromo; A represents (a); (b); (c); (d); or (e), as well as their pharmaceutically acceptable salts. The invention further relates to a process for the preparation of such compounds. The compounds of the invention are mGluR5 modulators and are therefore useful for the control and prevention of acute and/or chronic neurological disorders.